Changeflow GovPing Pharma & Drug Safety BCL-XL/BCL-2 Degraders and Uses Thereof
Routine Notice Added Final

BCL-XL/BCL-2 Degraders and Uses Thereof

Favicon for changeflow.com ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092057A1 for BCL-XL/BCL-2 degrader compounds and methods of using the same for treating conditions such as cancer. The application was filed on May 12, 2023, by inventors including Huijun Dong, Bin Yang, and others, and covers novel chemical compositions under CPC classifications including C07D 417/12, C07D 471/04, and related therapeutic uses.

What changed

The USPTO published a patent application (US20260092057A1) for BCL-XL/BCL-2 degrader compounds and their uses in treating diseases such as cancer (A61P 35/00). The application covers novel heterocyclic compounds classified under multiple C07D subclasses and pharmaceutical compositions containing them. The compounds are potential therapeutic agents targeting anti-apoptotic Bcl-2 family proteins.

Pharmaceutical companies and drug manufacturers developing oncology therapeutics should review this published application to assess potential freedom-to-operate considerations or licensing opportunities. Patent applications do not impose compliance obligations but represent published intellectual property claims that may affect competitive landscape. No regulatory deadlines or penalties apply to this notice.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

BCL-XL/BCL-2 DEGRADERS AND USES THEREOF

Application US20260092057A1 Kind: A1 Apr 02, 2026

Inventors

Huijun Dong, Bin Yang, Lewis Dale Pennington, Eamon Comer, Melissa Ford, Robert Aversa, Matthew M. Weiss, Xiao Zhu, Thijs Beuming

Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

CPC Classifications

C07D 417/12 A61K 31/496 A61K 31/635 A61P 35/00 C07D 207/16 C07D 401/12 C07D 417/14 C07D 471/04 C07D 471/08 C07D 471/10 C07D 487/04 C07D 487/08 C07D 487/10 C07D 519/00

Filing Date

2023-05-12

Application No.

18864802

View original document →

Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260092057A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Filing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.